|Mr. Michel Vounatsos||CEO & Director||3.11M||N/A||1962|
|Mr. Michael R. McDonnell CPA||Exec. VP & CFO||1.86M||N/A||1964|
|Ms. Susan H. Alexander Esq.||Exec. VP, Chief Legal Officer & Sec.||1.79M||N/A||1957|
|Ms. Robin C. Kramer||Sr. VP & Chief Accounting Officer||N/A||N/A||1966|
|Ms. Nicole Murphy||Head of Pharmaceutical Operations & Technology||N/A||N/A||N/A|
|Mr. Michael Hencke||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Natacha Gassenbach||Chief Communication Officer & Head of Corp. Affairs||N/A||N/A||N/A|
|Dr. Ginger Gregory||Exec. VP & Chief HR Officer||N/A||N/A||1968|
|Dr. Anabella Villalobos Ph.D.||Head of Biotherapeutics & Medicinal Sciences||N/A||N/A||N/A|
|Dr. Sanjay Jariwala||Sr. VP of Worldwide Medical||N/A||N/A||N/A|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc.’s ISS governance QualityScore as of 1 July 2022 is 7. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 3; Compensation: 8.